BIOLASE Announces a Pilot program with Einstein Healthcare Network’s Residency in Endodontic

March 30, 2021

BIOLASE notes the goal of the program is to offer residents hands-on experience with dental lasers that are already in use across the industry, allowing residents to immediately implement their training when joining a future practice.

“BIOLASE has a deep commitment to the endodontic specialty,” said John Beaver, President and CEO of BIOLASE. “It is important for us to live out our mission of advancing dentistry by empowering the next generation of endodontists from Einstein. We are honored to be part of not only the residents’ future careers by arming them with innovative technologies, but also the future relationships they will build with their patients by offering a less invasive and more positive experience.”

Einstein Healthcare Network’s residency in endodontics is one of the first hospital-based endodontic programs approved by the American Dental Association. The residency is a 24-month program that admits two residents each year, preparing graduates to practice, teach and conduct independent research.

“We are committed to actively seeking out ways to help our residents feel fully equipped to enter into endodontic practice after leaving our program,” said Frederic Barnett, DMD, Chairman of the Department of Dental Medicine, and Chair and Program Director of Postdoctoral Endodontics at Albert Einstein Medical Center in Philadelphia. “Partnering with BIOLASE to integrate laser assisted endodontic training early on in our residents’ careers allows us to tighten the learning curve, which can positively impact a practice’s bottom line and ultimately provide a better patient experience overall.”

The Waterlase dental laser offers various benefits for endodontists, from faster procedures to new treatment options. Educating endodontists about the benefits of dental lasers is part of BIOLASE’s continued effort to help improve patient experiences and outcomes. This announcement comes on the heels of the recently developed Waterlase Endo Academy, open to all Waterlase endodontists. Learn more about the benefits of laser dentistry in endodontics at biolase.com/betterendo.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”